Better Therapeutics, Inc.
BTTX
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 29.66% | 19.22% | 11.67% | 1.43% | -59.23% |
| Total Depreciation and Amortization | -57.72% | -66.47% | -80.48% | -44.79% | -4.34% |
| Total Amortization of Deferred Charges | 75.71% | 75.71% | 75.71% | 75.71% | -- |
| Total Other Non-Cash Items | -50.39% | -69.78% | -77.32% | -82.09% | -57.34% |
| Change in Net Operating Assets | 85.45% | 527.05% | 306.53% | 367.98% | -85.43% |
| Cash from Operations | 32.15% | 29.11% | 22.30% | 6.13% | -132.88% |
| Capital Expenditure | 65.12% | 49.19% | 1.06% | -92.73% | -578.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9.46% | -108.74% | -261.52% | -5.71% | -0.78% |
| Cash from Investing | -2.01% | -87.82% | -214.77% | -10.18% | -10.14% |
| Total Debt Issued | -100.00% | -100.00% | -79.17% | -82.56% | -26.13% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8,655.56% | 4,443.54% | 14,050.00% | 28,300.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -101.93% | -100.92% | -- | -- | -- |
| Cash from Financing | -80.12% | -91.89% | -92.83% | -92.69% | 189.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -182.35% | -185.21% | -185.14% | -161.39% | 626.87% |